Susquehanna International Group’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Susquehanna International Group’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-54,419	Closed	-$50.1K	–	13959
2022 Q4	$49K	Buy	54,419 +42,369	+352%	+$123K	﹤0.01%	11410
2022 Q3	$72K	Buy	+12,050	New	+$68.3K	﹤0.01%	11973
2022 Q2	–	Sell	-81,739	Closed	-$311K	–	14369
2022 Q1	$311K	Sell	81,739 -14,267	-15%	-$64.3K	﹤0.01%	10192
2021 Q4	$432K	Buy	96,006 +38,771	+68%	+$197K	﹤0.01%	9567
2021 Q3	$267K	Buy	57,235 +30,943	+118%	+$164K	﹤0.01%	10859
2021 Q2	$185K	Buy	+26,292	New	+$142K	﹤0.01%	11672
2020 Q3	–	Sell	-7,650	Closed	-$220K	–	11340
2020 Q2	$220K	Buy	+7,650	New	+$177K	﹤0.01%	8877

Susquehanna International Group's STSA Position: Q1 2023 in Review

Susquehanna International Group sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q1 2023, closing a stake of 54,419 shares — an estimated $50.1K sold.

Susquehanna International Group first reported a position in STSA in Q2 2020 and held it in 7 quarters. The position peaked at $432K in Q4 2021. 31 funds tracked by Wall St. Rank hold STSA as of Q1 2023.

Susquehanna International Group reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Susquehanna International Group sold 54,419 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $50.1K.
Susquehanna International Group first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
Susquehanna International Group's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $432K in Q4 2021.
31 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.